scispace - formally typeset
Open AccessJournal ArticleDOI

What is polypharmacy? A systematic review of definitions

TLDR
Numerical definitions of polypharmacy did not account for specific comorbidities present and make it difficult to assess safety and appropriateness of therapy in the clinical setting, according to a systematic review of existing literature.
Abstract
Multimorbidity and the associated use of multiple medicines (polypharmacy), is common in the older population. Despite this, there is no consensus definition for polypharmacy. A systematic review was conducted to identify and summarise polypharmacy definitions in existing literature. The reporting of this systematic review conforms to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) checklist. MEDLINE (Ovid), EMBASE and Cochrane were systematically searched, as well as grey literature, to identify articles which defined the term polypharmacy (without any limits on the types of definitions) and were in English, published between 1st January 2000 and 30th May 2016. Definitions were categorised as i. numerical only (using the number of medications to define polypharmacy), ii. numerical with an associated duration of therapy or healthcare setting (such as during hospital stay) or iii. Descriptive (using a brief description to define polypharmacy). A total of 1156 articles were identified and 110 articles met the inclusion criteria. Articles not only defined polypharmacy but associated terms such as minor and major polypharmacy. As a result, a total of 138 definitions of polypharmacy and associated terms were obtained. There were 111 numerical only definitions (80.4% of all definitions), 15 numerical definitions which incorporated a duration of therapy or healthcare setting (10.9%) and 12 descriptive definitions (8.7%). The most commonly reported definition of polypharmacy was the numerical definition of five or more medications daily (n = 51, 46.4% of articles), with definitions ranging from two or more to 11 or more medicines. Only 6.4% of articles classified the distinction between appropriate and inappropriate polypharmacy, using descriptive definitions to make this distinction. Polypharmacy definitions were variable. Numerical definitions of polypharmacy did not account for specific comorbidities present and make it difficult to assess safety and appropriateness of therapy in the clinical setting.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

3D Printing Pharmaceuticals: Drug Development to Frontline Care

TL;DR: This review provides a timely perspective on the motivations and potential applications of 3DP pharmaceuticals, as well as a practical viewpoint on how 3DP could be integrated across the pharmaceutical space.
Journal ArticleDOI

An update on the clinical consequences of polypharmacy in older adults: a narrative review

TL;DR: The issue of ‘confounding by multimorbidity’ has been underestimated and should be better accounted for in future studies, and researchers should develop more clinically relevant definitions of polypharmacy, including measures of inappropriate or problematic polyPharmacy.
Journal ArticleDOI

Alzheimer's Disease Microbiome Is Associated with Dysregulation of the Anti-Inflammatory P-Glycoprotein Pathway.

TL;DR: A potential nexus between the intestinal microbiome and AD is the modulation of intestinal homeostasis by increases in inflammatory, and decreases in anti-inflammatory, microbial metabolism that may underlie this neurodegenerative disorder.
Journal ArticleDOI

An overview of prevalence, determinants and health outcomes of polypharmacy:

TL;DR: It was showed that the prevalence of polypharmacy varied between 10% to as high as around 90% in different populations, and chronic conditions, demographics, socioeconomics and self-assessed health factors were independent predictors of polyPharmacy.
References
More filters
Journal ArticleDOI

Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts.

TL;DR: The application of the Beers criteria and other tools for identifying potentially inappropriate medication use will continue to enable providers to plan interventions for decreasing both drug-related costs and overall costs and thus minimize drug- related problems.
Journal ArticleDOI

Aging with multimorbidity: a systematic review of the literature

TL;DR: Methodological issues in evaluating multimorbidity are discussed as well as future research needs, especially concerning etiological factors, combinations and clustering of chronic diseases, and care models for persons affected by multiple disorders.
Journal ArticleDOI

Explicit Criteria for Determining Potentially Inappropriate Medication Use by the Elderly: An Update

TL;DR: In this article, a panel of experts agreed on the validity of 28 criteria describing the potentially inappropriate use of medication by general populations of the elderly as well as 35 criteria defining potentially inappropriate medication use in older persons known to have any of 15 common medical conditions.
Journal ArticleDOI

Clinical consequences of polypharmacy in elderly

TL;DR: It is shown that well-designed interprofessional intervention studies that focus on enrolling high-risk older patients with polypharmacy have shown that they can be effective in reducing aspects of unnecessary prescribing with mixed results on distal health outcomes.
Journal ArticleDOI

Reducing Inappropriate Polypharmacy: The Process of Deprescribing

TL;DR: A deprescribing protocol is proposed comprising 5 steps: ascertain all drugs the patient is currently taking and the reasons for each one, and prioritize drugs for discontinuation that have the lowest benefit-harm ratio and lowest likelihood of adverse withdrawal reactions or disease rebound syndromes.
Related Papers (5)